ceritinib
Sign in to saveAlso known as LDK378, NVP-LDK378-NX, N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide, compound 15b
Ceritinib (INN, trade name Zykadia ) is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014.
Research
804 papers- Ceritinib.2006
- Ceritinib.2012
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.Lancet (London, England) · 2017
- Ceritinib: A primer for pharmacists.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2017
- Ceritinib: first global approval.Drugs · 2014
via PubMed
~7 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Research and development
- Society and culture
- Economics
- Intellectual property
- Brand names
- References
- External links
{{Infobox drug | image = Ceritinib structure.svg | image_class = skin-invert-image | width = 275 | alt = | caption =
| pronounce = | tradename = Zykadia, others | Drugs.com = | MedlinePlus = a614027 | DailyMedID = Ceritinib | pregnancy_AU = | pregnancy_category = | routes_of_administration = By mouth | ATC_prefix = L01 | ATC_suffix = ED02
Excerpted from Wikipedia’s “ceritinib” article, available under the CC BY-SA 4.0 licence.